Similarly, in the K14-Cre mutTP53fl/fl transgenic mouse model of HNSCC treated with oral 4NQO, local delivery of anti-PD-1 immune checkpoint inhibition loaded on a hydrogel prevented progression to HNSCC [35]. The gene discussed is KRT14; the disease is head and neck squamous cell carcinoma.